Spyre Therapeutics, Inc. SYRE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s other income (expense)?
- Spyre Therapeutics, Inc. (SYRE) reported other income (expense) of -$23.36M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Spyre Therapeutics, Inc.'s other income (expense) decreased by 366.1% year-over-year, from $8.78M to -$23.36M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other income (expense)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s other income (expense) has grown at a 320.3% compound annual growth rate (CAGR), from $804K to $59.7M.
- What does other income (expense) mean?
- The net result of all income and expenses not related to the core business operations.
- How do you interpret other income (expense)?
- Fluctuations here can mask or inflate the company's true operational performance.
- How does other income (expense) compare across companies?
- Varies widely based on capital structure and treasury activities.